Drug General Information (ID: DDIFW17TPS)
Drug Name			Carfilzomib		Drug Info		Norgestrel		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Protease Inhibitors				Contraceptive Agents
Structure

Mechanism of Carfilzomib-Norgestrel Interaction (Severity Level: Major)
Additive thrombogenic effects Click to Show/Hide Mechanism Graph
Drug Name		Carfilzomib				Norgestrel
Mechanism		Thrombogenic effects				Thrombogenic effects
Key Mechanism Factor 1
		Factor Name		Thrombogenic effects
		Factor Description		Drug-induced thrombosis disrupts the balance between thrombogenic factors and protective mechanisms and tends to produce thrombosis. Drug-induced thrombosis usually causes venous thrombotic events, and arterial thrombotic events are also noted as a result of drug administration
Mechanism Description		Additive thrombogenic effects by the combination of Carfilzomib and Norgestrel

Recommended Action
Management		Hormonal contraception associated with a risk of thrombosis should generally be avoided during use of carfilzomib. Advise female and male patients of reproductive potential to use effective contraception or abstain from sexual activity during treatment with carfilzomib for at least 30 and 90 days, respectively, following completion of therapy. Advise the patient to contact their physician immediately if pregnancy does occur during these times.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".